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Background: Everolimus-eluting stents (EES) reduce adverse clinical outcomes com-
pared to first generation drug-eluting stents (DES) and cost less. Whether EES demon-
strate cost-effectiveness compared to DES within high risk patient subgroups is uncertain.
Methods: Percutaneous coronary intervention with EES (n1,003) and 1st generation
DES (n992) were performed at a single center (Wake Forest Baptist Medical Center)
between January 2007 and December 2010. One-year target lesion revascularization
(TLR) incidence and costs in 2010 dollars were prospectively evaluated and compared
within patient subgroups. Follow-up was 94% for both groups.
Results: Overall baseline characteristics were similar, except for higher use of EES for
ST-elevation myocardial infarction. Clopidogrel use at 1 year was 88% EES vs. 91% DES
(p0.02). Overall, EES was associated with 1.1 less TLR events per 100 patients
compared to DES. Aggregate 1-year costs were $765 less ($1,293 less to $197 less) with
EES (p0.005). EES demonstrated economic dominance (lower costs and TLR inci-
dence) compared to DES in all patient subgroups (see Table).
Cost effectiveness results for patient subgroups
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All patients
(N1995)
5172 5937 765 1.1 Dominant 98.6% Dominant 95.5%
Males
(n1399)
4997 5942 945 2.4 Dominant 99.2% Dominant 97.7%
Females
(n596)
5625 5927 303 0.6 Dominant 60.2% Dominant 47.4%
Age 75 y
(n356)
4598 6020 1421 4.1 Dominant 99.0% Dominant 98.2%
Age 75 y
(n1639)
5288 5918 630 1.3 Dominant 91.0% Dominant 81.7%
Diabetics
(n655)
5462 6673 1211 3.6 Dominant 97.7% Dominant 94.3%
Non-
diabetics
(n1340)
5032 5574 542 0.9 Dominant 89.8% Dominant 80.1%
ST-
elevation
MI
(n419)
4776 5303 527 0.1 Dominant 45.0% Dominant 57.6%
Non-ST-
elevation
ACS
(n1197)
5221 6065 844 2.5 Dominant 98.5% Dominant 93.6%
Off-label
indications
(n1607)
5388 6218 830 2.2 Dominant 98.4% Dominant 95.9%
On-label
indications
(n388)
4343 4681 338 0.3 Dominant 55.1% Dominant 49.7%
*Percentages based on 1,000 bootstrap resamplings. ACS indicates acute coronary syndrome; MI,
myocardial infarction; QALY, quality adjusted life year; TLR, target lesion revascularization.
Conclusions: In this prospective observational registry EES was economically dominant
compared to 1st generation DES in a variety of patient subgroups, including PCI for acute
coronary syndrome and off-label indications.
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Background: The RESOLUTE International (R-INT) trial has demonstrated the safety
and effectiveness of the Resolute zotarolimus-eluting stent (R-ZES) through 2 years in a
real-world population of patients with coronary artery disease requiring percutaneous
coronary intervention (PCI). Concerns regarding long-term safety of drug-eluting stents,
particularly in complex patients and lesions, require ongoing follow-up of clinical trials to
confirm safety and effectiveness.
Methods: The R-INT observational trial prospectively enrolled 2349 patients at centers
across Europe, Argentina, India, and South Africa to undergo PCI using the R-ZES.
Minimal exclusion criteria assured a broad representation of real-world clinical practice.
The primary endpoint was a composite of cardiac death and target-vessel myocardial
infarction (CD/TV-MI). A key secondary endpoint was ARC definite and probable stent
thrombosis. Dual antiplatelet therapy with aspirin and clopidogrel was recommended for
6 months and was prescribed thereafter at operator’s discretion. Death, TV-MI, stent
thrombosis, and target vessel revascularization (TVR) events were adjudicated using the
same definitions and criteria as employed in the Global RESOLUTE Clinical Program.
Results: Two year follow-up was available for 2296 (97.7%) of patients enrolled.
Baseline characteristics include 78% males, mean age of 63.5 years, with 20% presenting
with acute MI and 26.1% with unstable angina; 30.5% of patients had diabetes mellitus.
Two-thirds of the patients were considered complex based on clinical and lesion
characteristics. At 2 years 43.9% of patients were receiving dual antiplatelet therapy. Two
year clinical outcomes include 5.9% CD/TV-MI, 4.5% death, 4.9% target lesion
revascularization, and 6.3% TVR. Very late definite and probable stent thrombosis was
0.1% for the period between 1to 2 years.
Conclusions: At 2 years after R-ZES implantation there is a very low rate of stent
thrombosis and clinical event rates are consistent with 2 year results in 1121 patients
treated with a R-ZES in the RESOLUTE All Comers trial. The final 3 year clinical
follow-up of this large, observational study will be reported.
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Background: Qvanteq has applied its novel coating-free bioactive surface technology
onto bare metal stents (BMS).
Methods: In-Vivo: Integrity BMS, Qvanteq-treated Integrity stents (QBM), and Resolute
DES were randomly implanted in a swine coronary artery model up to 90d with
angiographic and histopathological assessments. In-Vitro: treated (QBM) and untreated
CoCr disks were incubated with heparinized human blood for 2 hrs and the adherent blood
components were investigated by immunofluorescence microscopy or SEM. Proliferation
assays were performed using human aortic endothelial cells for up to 96 hrs.
Results: In-Vivo: Quantitative angiography demonstrated a reduction (p0.05) of late
lumen loss and percent stenosis in QBM compared to BMS at 30d and DES at 30 and 90d.
Neointimal area was decreased (p0.05) in QBM compared to BMS and DES. Light
microscopy showed vascular injury, inflammation, and adventitial fibrosis of the QBM
was reduced (p0.05) compared to DES at 30d. Endothelialization was complete in the
QBM and BMS groups and near complete in the DES group. Analogous results were
obtained with treated Multi-Link and Omega stents compared to their untreated BMS and
DES counterparts. In-Vitro: A 10-fold decrease in platelet adhesion and a 5-fold increase
in neutrophil recruitment were observed on the QBM surface compared to the untreated
surface. Proliferative endothelial cell assays at 2d were slightly higher for QBM
(85.8%3.2 coverage) compared to untreated surfaces (78.6%11.2). At 4d cell growth
was comparable with confluent cell coverage on both surfaces (95% coverage).
Conclusions: The QBM surface significantly reduced neointimal hyperplasia in swine
coronaries compared to both BMS and DES, independently from stent design and/or
alloy, without adverse vascular healing effects. In-Vitro data indicate that those results
may be related to a significant reduction of adherent platelets combined with enhanced
neutrophil adhesion, which promote reendothelialization and decrease neointimal hyper-
plasia by locally regulating acute inflammatory response and endothelial recovery.
Therefore, this novel approach may be an effective alternative to DES in reducing clinical
in-stent restenosis.
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Background: Although incidence of initial restenosis in coronary stenting lesions was
dramatically decreased by use of drug-eluting stent (DES), few data exist regarding late
catch-up restenosis of DES during long term follow-up in Japanese patients. Therefore,
we clarified the efficacy of DES for restenosis in the initial and late catch-up in
comparison with those of bare metal stent (BMS).
Methods: We analyzed 1478 lesions of BMS and 2959 of DES. DESs consisted of the
2091 sirolimus (SES; Cypher & Cypher-Select), 357 paclitaxel (PES; Taxus & Taxus-
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